B cell targeted therapy in autoimmunity

Journal of Autoimmunity

Volumn 28, Issue 2-3, 2007, Pages 62-68

  Blank, Miri ^a,b   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoantibodies; Autoimmunity; B cell; Therapy

Indexed keywords

ABATACEPT; ANTIBODY; AUTOANTIBODY; CD22 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; DNA VACCINE; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5D12; MONOCLONAL ANTIBODY B LYMPHOCYTE STIMULATOR; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY H4B4; RITUXIMAB; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ALOPECIA; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CARDIOMYOPATHY; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CROHN DISEASE; DNA IMMUNIZATION; FIBROSIS; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; JUVENILE DIABETES MELLITUS; LONG TERM CARE; LYMPHADENITIS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NECROTIZING ARTERITIS; NONHUMAN; PATHOGENESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE INJURY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; RECEPTORS, ANTIGEN, B-CELL; SELF TOLERANCE;

EID: 34247562214     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.02.001     Document Type: Review

References (84)

1. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2 9 (2001) 764-766
2. Carreno B.M., and Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20 (2002) 29-53
3. Silverman G.J. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci 12 (2007) 2194-2206
4. Silverman G.J. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheumatism 54 8 (2006) 2356-2367
5. Martin F., and Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24 (2006) 467-496
6. Dorner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 77 (2006) 3-11
7. Lederman S., Cleary A.M., Yellin M.J., Frank D.M., Karpusas M., Thomas D.W., et al. The central role of the CD40-ligand and CD40 pathway in T-lymphocyte-mediated differentiation of B lymphocytes. Curr Opin Hematol 3 1 (1996) 77-86
8. Diehl L., Den Boer A.T., van der Voort E.I., Melief C.J., Offringa R., and Toes R.E. The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med 78 7 (2000) 363-371
9. Reiser H., and Stadecker M.J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335 18 (1996) 1369-1377
10. Mihara M., Tan I., Chuzhin Y., Reddy B., Budhai L., Holzer A., et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 106 1 (2000) 91-101
11. Davidson A., Wang X., Mihara M., Ramanujam M., Huang W., Schiffer L., et al. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann NY Acad Sci 987 (2003) 188-198
12. Prud'homme G.J., Chang Y., and Li X. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum Gene Ther 13 3 (2002) 395-406
13. Takiguchi M., Murakami M., Nakagawa I., Saito I., Hashimoto A., and Uede T. CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. Life Sci 66 11 (2000) 991-1001
14. Grammer A.C., and Lipsky P.E. CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv Immunol 76 (2000) 61-178
15. Kalled S.L., Cutler A.H., and Burkly L.C. Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. J Immunol 167 3 (2001) 1740-1747
16. Wang X., Huang W., Schiffer L.E., Mihara M., Akkerman A., Hiromatsu K., et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 48 2 (2003) 495-506
17. Durie F.H., Fava R.A., Foy T.M., Aruffo A., Ledbetter J.A., and Noelle R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261 5126 (1993) 1328-1330
18. Gerritse K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J., et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 93 6 (1996) 2499-2504
19. Durie F.H., Aruffo A., Ledbetter J., Crassi K.M., Green W.R., Fast L.D., et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 94 3 (1994) 1333-1338
20. Huang W., Sinha J., Newman J., Reddy B., Budhai L., Furie R., et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 46 6 (2002) 1554-1562
21. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 3 (2003) 719-727
22. Kalunian K.C., Davis Jr. J.C., Merrill J.T., Totoritis M.C., and Wofsy D. IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 12 (2002) 3251-3258
23. Boon L., Laman J.D., Ortiz-Buijsse A., den Hartog M.T., Hoffenberg S., Liu P., et al. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 174 1 (2002) 53-65
24. Mullberg J., Althoff K., Jostock T., and Rose-John S. The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 11 1 (2002) 27-38
25. Vakkalanka R.K., Woo C., Kirou K.A., Koshy M., Berger D., and Crow M.K. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42 5 (1999) 871-881
26. Tamura N., Kobayashi S., Kato K., Bando H., Haruta K., Oyanagi M., et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 28 12 (2001) 2583-2590
27. Vinay D.S., and Kwon B.S. Role of 4-1BB in immune responses. Semin Immunol 10 6 (1998) 481-489
28. Bukczynski J., Wen T., and Watts T.H. Costimulation of human CD28- T cells by 4-1BB. ligand Eur J Immunol 33 2 (2003) 446-454
29. Sun Y., Chen H.M., Subudhi S.K., Chen J., Koka R., Chen L., et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8 12 (2002) 1404-1413
30. Foell J., Strahotin S., O'Neil S.P., McCausland M.M., Suwyn C., Haber M., et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB × NZW F1 mice. J Clin Invest 111 10 (2003) 1505-1518
31. Hong H.J., Lee J.W., Park S.S., Kang Y.J., Chang S.Y., Kim K.M., et al. A humanized anti-4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J Immunother 23 6 (2000) 613-621
32. Zhou T, Zhang J, Carter R, Kimberly R. BLyS and B cell autoimmunity. Nemazee D (edt): B cell Biology in Autoimmunity. Curr Dir Autoimmun, Basel, Karger, Theofilopoulos AN(ed) 2003;6,21-37.
33. Kalled S.L., Ambrose C., and Hsu Y.M. BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets 7 1 (2003) 115-123
34. Bossen C., and Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18 5 (2006) 263-275
35. Giri J., Roschke V., Nardelli B., Carrell J., Sosnovtseva S., Greenfield W., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285 5425 (1999) 260-263
36. Do R.K., Hatada E., Lee H., Tourigny M.R., Hilbert D., and Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192 7 (2000) 953-964
37. Laabi Y., and Strasser A. Immunology. Lymphocyte survival-ignorance is BLys. Science 289 (2000) 883-884
38. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 6781 (2000) 995-999
39. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166 1 (2001) 6-10
40. Cheema G.S., Roschke V., Hilbert D.M., and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44 6 (2001) 1313-1319
41. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109 1 (2002) 59-68
42. Mackay I.R., Groom J., and Mackay C.R. Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 35 8 (2002) 551-553
43. Khare S.D., Sarosi I., Xia X.Z., McCabe S., Miner K., Solovyev I., et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 97 7 (2000) 3370-3374
44. Yan M., Wang H., Chan B., Roose-Girma M., Erickson S., Baker T., et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2 7 (2001) 638-643
45. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002;17(4):515-24.
46. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48 11 (2003) 3253-3265
47. Zhang HG, Yang P, Xie J, Liu Z, Liu D, Xiu L, et al. Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice. J Immunol 168(8):4164-72.
48. Sabahi R., and Anolik J.H. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66 15 (2006) 1933-1948
49. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B-cells in vivo by a chimeric mouse monoclonal antibody to CD20. Blood 83 2 (1994) 435-445
50. Sanz I., Anolik J.H., and Looney R.J. B cell depletion therapy in autoimmune diseases. Front Biosci 12 (2007) 2546-6
51. Levine T.D., and Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52 8 (1999) 1701-1704
52. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 4 (2001) 952-957
53. Patel K., Berman J., Ferber A., and Caro J. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol 67 1 (2001) 59-60
54. Zaja F., Russo D., Fuga G., Perella G., and Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55 7 (2000) 1062-1063
55. Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., and Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 116 2 (2002) 465-467
56. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 10 (2002) 2673-2677
57. Specks U., Fervenza F.C., McDonald T.J., and Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44 12 (2001) 2836-2840
58. Saleh M.N., Gutheil J., Moore M., Bunch P.W., Butler J., Kunkel L., et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27 6 Suppl. 12 (2000) 99-103
59. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., and Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358 9292 (2001) 1511-1513
60. Oligino T.J., and Dalrymple S.A. Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Res Ther 5 Suppl. 4 (2003) S7-S11
61. Arzoo K., Sadeghi S., and Liebman H.A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61 10 (2002) 922-924
62. Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48 8 (2003) 2146-2154
63. Tuscano J.M., Harris G.S., and Tedder T.F. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun Rev 2 2 (2003) 101-108
64. Juweid M. Technology evaluation: epratuzumab, Immunomedics/Amgen. Curr Opin Mol Ther 5 2 (2003) 192-198
65. Lee C.H., Suh C.H., Lee J., Kim Y.T., and Lee S.K. The effects of anti-idiotypic antibody on antibody production and apoptosis of anti-dsDNA antibody producing cells. Clin Exp Rheumatol 21 3 (2003) 291-300
66. Sherer Y., Levy Y., and Shoenfeld Y. IVIG in autoimmunity and cancer: efficacy versus safety. Expert Opin Drug Saf 1 2 (2002) 153-158
67. Sewell W.A., and Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 107 4 (2002) 384-393
68. Prasad N.K.A., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
69. Zandman-Goddard G., and Shoenfeld Y. Novel approaches to therapy for SLE. Clin Rev Allergy Immunol 25 1 (2003) 105-112
70. Tarrant T.K., Frazer D.H., Aya-Ay J.P., and Patel D.D. B cell loss leading to remission in severe systemic lupus erythematosus. J Rheumatol 30 2 (2003) 412-414
71. Amital H., Rewald E., Levy Y., Bar-Dayan Y., Manthorpe R., Engervall P., et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 62 2 (2003) 175-177
72. Shoenfeld Y., Krause I., and Blank M. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Ann Rheum Dis 56 1 (1997) 5-11
73. Vassilev T., Yamamoto M., Aissaoui A., Bonnin E., Berrih-Aknin S., Kazatchkine M.D., et al. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol 29 8 (1999) 2436-2442
74. Blank M., Levy Y., Amital H., Pines M., Genina O., and Shoenfeld Y. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46 6 (2002) 1689-1690
75. Shoenfeld Y., Rauova L., Gilburd B., Kvapil F., Goldberg I., Kopolovic J., et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14 11 (2002) 1303-1311
76. Krause I., Blank M., Sherer Y., Gilburd B., Kvapil F., and Shoenfeld Y. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 32 12 (2002) 3414-3424
77. Krause I., Blank M., and Shoenfeld Y. Peptide immunotherapy in autoimmune diseases. Drug News Perspect 13 2 (2000) 78-84
78. Blank M., Shoenfeld Y., Cabilly S., Heldman Y., Fridkin M., and Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A 96 9 (1999) 5164-5168
79. Alarcon-Segovia D., Tumlin J.A., Furie R.A., McKay J.D., Cardiel M.H., Strand V., et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 8 2 (2003) 442-454
80. Merrill J.T. LJP 1082: a toleragen for Hughes syndrome. Lupus 13 5 (2004) 335-338
81. Pritchard N.R., and Smith K.G. B cell inhibitory receptors and autoimmunity. Immunology 108 3 (2003) 263-273
82. Bolland S., and Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13 2 (2000) 277-285
83. Fukuyama H., Nimmerjahn F., and Ravetch J.V. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 6 1 (2005) 99-106
84. McGaha T.L., Sorrentino B., and Ravetch J.V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307 5709 (2005) 590-593